Pfizer's $2.3B Trillium Deal Closes Without FTC Challenge
Pfizer finished up its $2.3 billion takeover of blood cancer drugmaker Trillium Therapeutics on Wednesday after the Federal Trade Commission's time to raise antitrust concerns pre-merger ran out....To view the full article, register now.
Already a subscriber? Click here to view full article